메뉴 건너뛰기




Volumn 123, Issue 10, 2017, Pages 1721-1730

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes

Author keywords

BRCA2; breast cancer type 1 (BRCA1); hereditary breast and ovarian cancer; panel testing; triple negative breast cancer

Indexed keywords

ATM PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; ATM PROTEIN, HUMAN; BARD1 PROTEIN, HUMAN; BRIP1 PROTEIN, HUMAN; CHEK2 PROTEIN, HUMAN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; RAD51C PROTEIN, HUMAN; RNA HELICASE; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

EID: 85009723317     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30498     Document Type: Article
Times cited : (317)

References (40)
  • 1
    • 0038744296 scopus 로고    scopus 로고
    • Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
    • Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130.
    • (2003) Am J Hum Genet , vol.72 , pp. 1117-1130
    • Antoniou, A.1    Pharoah, P.D.2    Narod, S.3
  • 2
    • 34248170114 scopus 로고    scopus 로고
    • Meta-analysis of BRCA1 and BRCA2 penetrance
    • Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–1333.
    • (2007) J Clin Oncol , vol.25 , pp. 1329-1333
    • Chen, S.1    Parmigiani, G.2
  • 3
    • 0028330276 scopus 로고
    • Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
    • Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692–695.
    • (1994) Lancet , vol.343 , pp. 692-695
    • Ford, D.1    Easton, D.F.2    Bishop, D.T.3    Narod, S.A.4    Goldgar, D.E.5
  • 5
    • 84883625609 scopus 로고    scopus 로고
    • Hereditary breast cancer: ever more pieces to the polygenic puzzle
    • Bogdanova N, Helbig S, Dork T. Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract. 2013;11:12.
    • (2013) Hered Cancer Clin Pract , vol.11 , pp. 12
    • Bogdanova, N.1    Helbig, S.2    Dork, T.3
  • 6
    • 58849157647 scopus 로고    scopus 로고
    • Cowden syndrome: a critical review of the clinical literature
    • Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns. 2009;18:13–27.
    • (2009) J Genet Couns , vol.18 , pp. 13-27
    • Pilarski, R.1
  • 7
    • 0142157701 scopus 로고    scopus 로고
    • Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
    • Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63:6643–6650.
    • (2003) Cancer Res , vol.63 , pp. 6643-6650
    • Olivier, M.1    Goldgar, D.E.2    Sodha, N.3
  • 8
    • 0033738748 scopus 로고    scopus 로고
    • Will the real Cowden syndrome please stand up: revised diagnostic criteria
    • Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000;37:828–830.
    • (2000) J Med Genet , vol.37 , pp. 828-830
    • Eng, C.1
  • 9
    • 33744782567 scopus 로고    scopus 로고
    • Frequency and spectrum of cancers in the Peutz-Jeghers syndrome
    • Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209–3215.
    • (2006) Clin Cancer Res , vol.12 , pp. 3209-3215
    • Hearle, N.1    Schumacher, V.2    Menko, F.H.3
  • 10
    • 0035211026 scopus 로고    scopus 로고
    • Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families
    • Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–1353.
    • (2001) Gastroenterology , vol.121 , pp. 1348-1353
    • Pharoah, P.D.1    Guilford, P.2    Caldas, C.3
  • 11
    • 34249989159 scopus 로고    scopus 로고
    • Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer
    • Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360–2372.
    • (2007) JAMA , vol.297 , pp. 2360-2372
    • Kaurah, P.1    MacMillan, A.2    Boyd, N.3
  • 12
    • 80053100604 scopus 로고    scopus 로고
    • Rare variants in the ATM gene and risk of breast cancer [serial online]
    • Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer [serial online]. Breast Cancer Res. 2011;13:R73.
    • (2011) Breast Cancer Res , vol.13 , pp. R73
    • Goldgar, D.E.1    Healey, S.2    Dowty, J.G.3
  • 13
    • 80053594059 scopus 로고    scopus 로고
    • Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer
    • Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29:3747–3752.
    • (2011) J Clin Oncol , vol.29 , pp. 3747-3752
    • Cybulski, C.1    Wokolorczyk, D.2    Jakubowska, A.3
  • 14
    • 39149141409 scopus 로고    scopus 로고
    • CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls
    • Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26:542–548.
    • (2008) J Clin Oncol , vol.26 , pp. 542-548
    • Weischer, M.1    Bojesen, S.E.2    Ellervik, C.3    Tybjaerg-Hansen, A.4    Nordestgaard, B.G.5
  • 15
    • 84908145253 scopus 로고    scopus 로고
    • Breast-cancer risk in families with mutations in PALB2
    • Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:497–506.
    • (2014) N Engl J Med , vol.371 , pp. 497-506
    • Antoniou, A.C.1    Casadei, S.2    Heikkinen, T.3
  • 16
    • 84973288294 scopus 로고    scopus 로고
    • Version 2.2016. NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA NCCN, Accessed March 3, 2016
    • Daly M, Pilarski R, Axilbund JE, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2016. NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA: NCCN; 2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed March 3, 2016.
    • (2016) Genetic/Familial High-Risk Assessment: Breast and Ovarian
    • Daly, M.1    Pilarski, R.2    Axilbund, J.E.3
  • 17
    • 84921898753 scopus 로고    scopus 로고
    • Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer
    • Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clinl Oncol. 2015;33:304–311.
    • (2015) J Clinl Oncol , vol.33 , pp. 304-311
    • Couch, F.J.1    Hart, S.N.2    Sharma, P.3
  • 18
    • 84965090778 scopus 로고    scopus 로고
    • Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment
    • Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1:943–951.
    • (2015) JAMA Oncol , vol.1 , pp. 943-951
    • Desmond, A.1    Kurian, A.W.2    Gabree, M.3
  • 19
    • 84930531402 scopus 로고    scopus 로고
    • Gene-panel sequencing and the prediction of breast-cancer risk
    • Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243–2257.
    • (2015) N Engl J Med , vol.372 , pp. 2243-2257
    • Easton, D.F.1    Pharoah, P.D.2    Antoniou, A.C.3
  • 20
    • 84918798338 scopus 로고    scopus 로고
    • Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel
    • Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121:25–33.
    • (2015) Cancer , vol.121 , pp. 25-33
    • Tung, N.1    Battelli, C.2    Allen, B.3
  • 21
    • 77957967823 scopus 로고    scopus 로고
    • Expanding the criteria for BRCA mutation testing in breast cancer survivors
    • Kwon JS, Daniels MS, Sun CC, Lu KH. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28:4214–4220.
    • (2010) J Clin Oncol , vol.28 , pp. 4214-4220
    • Kwon, J.S.1    Daniels, M.S.2    Sun, C.C.3    Lu, K.H.4
  • 22
    • 84890247728 scopus 로고    scopus 로고
    • Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis
    • Tun NM, Villani G, Ong K, Yoe L, Bo ZM. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet. 2014;85:43–48.
    • (2014) Clin Genet , vol.85 , pp. 43-48
    • Tun, N.M.1    Villani, G.2    Ong, K.3    Yoe, L.4    Bo, Z.M.5
  • 23
    • 84856770553 scopus 로고    scopus 로고
    • Early onset HER2-positive breast cancer is associated with germline TP53 mutations
    • Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012;118:908–913.
    • (2012) Cancer , vol.118 , pp. 908-913
    • Melhem-Bertrandt, A.1    Bojadzieva, J.2    Ready, K.J.3
  • 24
    • 78149335586 scopus 로고    scopus 로고
    • A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations
    • Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 2010;47:771–774.
    • (2010) J Med Genet , vol.47 , pp. 771-774
    • Wilson, J.R.1    Bateman, A.C.2    Hanson, H.3
  • 25
    • 84965051096 scopus 로고    scopus 로고
    • Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of breast cancer patients
    • Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of breast cancer patients. J Clin Oncol. 2016;34:1460–1468.
    • (2016) J Clin Oncol , vol.34 , pp. 1460-1468
    • Tung, N.1    Lin, N.U.2    Kidd, J.3
  • 26
    • 84907597238 scopus 로고    scopus 로고
    • A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes
    • Eggington JM, Bowles KR, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet. 2014;86:229–237.
    • (2014) Clin Genet , vol.86 , pp. 229-237
    • Eggington, J.M.1    Bowles, K.R.2    Moyes, K.3
  • 27
    • 84928209346 scopus 로고    scopus 로고
    • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
    • Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
    • (2015) Genet Med , vol.17 , pp. 405-424
    • Richards, S.1    Aziz, N.2    Bale, S.3
  • 29
    • 0029794992 scopus 로고    scopus 로고
    • Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
    • Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–187.
    • (1996) Nat Genet , vol.14 , pp. 185-187
    • Roa, B.B.1    Boyd, A.A.2    Volcik, K.3    Richards, C.S.4
  • 30
    • 84964999648 scopus 로고    scopus 로고
    • Panel testing for familial breast cancer: calibrating the tension between research and clinical care
    • Thompson ER, Rowley SM, Li N, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol. 2016;34:1455–1459.
    • (2016) J Clin Oncol , vol.34 , pp. 1455-1459
    • Thompson, E.R.1    Rowley, S.M.2    Li, N.3
  • 31
    • 85019281384 scopus 로고    scopus 로고
    • Presented Abstracts from the 33rd Annual Education Conference of the National Society of Genetic Counselors; New Orleans, LA; September 2014. Detection of pathogenic mutations in moderate penetrance breast cancer genes significantly increases the number of patients identified as candidates for increased screening [abstract]
    • Rosenthal E, McCoy H, Moyes K, Evans B, Wenstrup R. Presented Abstracts from the 33rd Annual Education Conference of the National Society of Genetic Counselors; New Orleans, LA; September 2014. Detection of pathogenic mutations in moderate penetrance breast cancer genes significantly increases the number of patients identified as candidates for increased screening [abstract]. J Genet Couns. 2014;23:1100.
    • (2014) J Genet Couns , vol.23 , pp. 1100
    • Rosenthal, E.1    McCoy, H.2    Moyes, K.3    Evans, B.4    Wenstrup, R.5
  • 32
    • 84952630873 scopus 로고    scopus 로고
    • Rescreening for genetic mutations using multigene panel testing in patients who previously underwent non-informative genetic screening
    • Frey MK, Kim SH, Bassett RY, et al. Rescreening for genetic mutations using multigene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol. 2015;139:211–215.
    • (2015) Gynecol Oncol , vol.139 , pp. 211-215
    • Frey, M.K.1    Kim, S.H.2    Bassett, R.Y.3
  • 33
    • 84952642532 scopus 로고    scopus 로고
    • A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients
    • Lincoln SE, Kobayashi Y, Anderson MJ, et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J Mol Diagn. 2015;17:533–544.
    • (2015) J Mol Diagn. , vol.17 , pp. 533-544
    • Lincoln, S.E.1    Kobayashi, Y.2    Anderson, M.J.3
  • 34
    • 84885853847 scopus 로고    scopus 로고
    • Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress
    • Culver JO, Brinkerhoff CD, Clague J, et al. Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet. 2013;84:464–472.
    • (2013) Clin Genet , vol.84 , pp. 464-472
    • Culver, J.O.1    Brinkerhoff, C.D.2    Clague, J.3
  • 36
    • 9744252310 scopus 로고    scopus 로고
    • Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message
    • van Dijk S, van Asperen CJ, Jacobi CE, et al. Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message. Genet Test. 2004;8:235–239.
    • (2004) Genet Test , vol.8 , pp. 235-239
    • van Dijk, S.1    van Asperen, C.J.2    Jacobi, C.E.3
  • 37
    • 85019273134 scopus 로고    scopus 로고
    • Safety of multiplex gene testing for inherited cancer risk: interim analysis of a clinical trial [abstract]
    • Kurian AW, Idos G, Culver J, et al. Safety of multiplex gene testing for inherited cancer risk: interim analysis of a clinical trial [abstract]. J Clin Oncol. 2016;34(15S). Abstract 1503.
    • (2016) J Clin Oncol , vol.34 , Issue.15S
    • Kurian, A.W.1    Idos, G.2    Culver, J.3
  • 38
    • 84861323251 scopus 로고    scopus 로고
    • Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer
    • Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–2795.
    • (2012) Cancer , vol.118 , pp. 2787-2795
    • Hartman, A.R.1    Kaldate, R.R.2    Sailer, L.M.3
  • 39
    • 68149168181 scopus 로고    scopus 로고
    • Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy [abstract]
    • Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy [abstract]. J Clin Oncol. 2009;27(15S). Abstract 551.
    • (2009) J Clin Oncol , vol.27 , Issue.15S
    • Ryan, P.D.1    Tung, N.M.2    Isakoff, S.J.3
  • 40
    • 77949908546 scopus 로고    scopus 로고
    • Efficacy of neoadjuvant cisplatin in triple-negative breast cancer
    • Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145–1153.
    • (2010) J Clin Oncol , vol.28 , pp. 1145-1153
    • Silver, D.P.1    Richardson, A.L.2    Eklund, A.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.